Mycophenolate mofetil as second line therapy in autoimmune hepatitis?

American Journal of Gastroenterology

Volumn 103, Issue 12, 2008, Pages 3063-3070

  Hennes, Elke M ^a   Oo, Ye H ^b   Schramm, Christoph ^a   Denzer, Ulrike ^a   Buggisch, Peter ^a   Wiegard, Christiane ^a   Kanzler, Stephan ^c   Schuchmann, Marcus ^c   Boecher, Wulf ^c   Galle, Peter R ^c   Adams, David H ^b   Lohse, Ansgar W ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TREATMENT OUTCOME;

ADULT; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 58149390145     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02180.x     Document Type: Article

References (27)

1. Krawitt Edward L. Autoimmune hepatitis. N Engl J Med 2006 354 : 54 66.
2. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 1972 63 : 820 33.
3. Czaja AJ, Davis GL, Ludwig J, et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983 85 : 713 7.
4. Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988 8 : 781 4.
5. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 1972 63 : 820 33.
6. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973 1 : 735 7.
7. Crapper RM, Bhathal PS, Mackay IR, et al. 'Acute' autoimmune hepatitis. Digestion 1986 34 : 216 25.
8. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999 30 : 222 7.
9. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995 90 : 771 6.
10. Kanzler S, Gerken G, Dienes HP, et al. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997 35 : 571 8.
11. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998 29 : 990 93.
12. Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988 8 : 781 4.
13. Johnson PJ and McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993 18 : 998 1005.
14. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995 333 : 958 63.
15. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001 46 : 1321 7.
16. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999 30 : 222 7.
17. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995 90 : 771 6.
18. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998 29 : 990 3.
19. Kanzler S, Gerken G, Dienes HP, et al. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997 35 : 571 8.
20. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995 345 : 1321 5.
21. Ross DJ, Waters PF, Levine M, et al. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: Preliminary experience. J Heart Lung Transplant 1998 17 : 768 74.
22. Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy 1997 17 : 1178 97.
23. Paterson DL, Singh N, Panebianco A, et al. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 1998 66 : 593 8.
24. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000 33 : 371 5.
25. Devlin SM, Swain MG, Urbanski SJ, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004 18 : 321 6.
26. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: The Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005 25 : 723 7.
27. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007 5 : 795 802.